Krediet Erwin, Janssen Debbie Ga, Heerdink Eibert R, Egberts Toine Cg, Vermetten Eric
Department of Psychiatry, Leiden University Medical Center, Leiden, Netherlands; ARQ National Psychotrauma Center, Diemen, Netherlands.
Expert Centre of Military Pharmacy, Primary Healthcare Institute, Ministry of Defence, Utrecht, Netherlands.
Eur Neuropsychopharmacol. 2020 Jul;36:244-254. doi: 10.1016/j.euroneuro.2020.04.009. Epub 2020 Jun 20.
Posttraumatic stress disorder (PTSD) is an often chronic condition for which currently available medications have limited efficacy. Medical cannabis is increasingly used to treat patients with PTSD; however, evidence for the efficacy and safety of cannabinoids is scarce. To learn more about patients' opinions on and experiences with medical cannabis, we organized a focus group discussion among military veterans (N = 7) with chronic PTSD who were treated with medical cannabis. Afterwards, some of their partners (N = 4) joined the group for an evaluation, during which they shared their perspective on their partner's use of medical cannabis. Both sessions were audio-recorded, transcribed verbatim, and analyzed by means of qualitative content analysis. Five overarching themes were identified. The first four themes related to the different phases of medical cannabis use - namely, 1) Consideration; 2) Initiation; 3) Usage; and 4) Discontinuation. The fifth theme related to several general aspects of medical cannabis use. Patients used medical cannabis to manage their symptoms and did not experience an urge to "get high." They used a variety of different cannabis strains and dosages and reported several therapeutic effects, including an increased quality of sleep. Furthermore, discussions about the experienced stigma surrounding cannabis generated insights with implications for the initiation of medical cannabis use. These results underscore the value of qualitative research in this field and are relevant for the design of future clinical trials on the use of medical cannabis for the treatment of PTSD.
创伤后应激障碍(PTSD)通常是一种慢性病,目前可用的药物疗效有限。医用大麻越来越多地用于治疗创伤后应激障碍患者;然而,关于大麻素疗效和安全性的证据却很少。为了更多地了解患者对医用大麻的看法和使用体验,我们组织了一次焦点小组讨论,参与者是7名患有慢性创伤后应激障碍且正在接受医用大麻治疗的退伍军人。之后,他们的一些伴侣(4名)加入该小组进行评估,期间他们分享了对伴侣使用医用大麻的看法。两次会议均进行了录音,逐字转录,并通过定性内容分析进行了分析。确定了五个总体主题。前四个主题与医用大麻使用的不同阶段有关,即:1)考虑;2)开始使用;3)使用;4)停止使用。第五个主题与医用大麻使用的几个一般方面有关。患者使用医用大麻来控制症状,没有“寻求快感”的冲动。他们使用了各种不同的大麻品种和剂量,并报告了几种治疗效果,包括睡眠质量提高。此外,关于围绕大麻的耻辱感的讨论产生了对开始使用医用大麻有影响的见解。这些结果强调了该领域定性研究的价值,并且与未来关于使用医用大麻治疗创伤后应激障碍的临床试验设计相关。